UniSuper Management Pty Ltd Purchases 2,063 Shares of DaVita Inc. (NYSE:DVA)

UniSuper Management Pty Ltd raised its position in DaVita Inc. (NYSE:DVA) by 21.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,506 shares of the company’s stock after purchasing an additional 2,063 shares during the period. UniSuper Management Pty Ltd’s holdings in DaVita were worth $1,721,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of DVA. MML Investors Services LLC increased its position in shares of DaVita by 1.3% in the 3rd quarter. MML Investors Services LLC now owns 5,300 shares of the company’s stock valued at $869,000 after buying an additional 68 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of DaVita by 8.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company’s stock worth $133,000 after acquiring an additional 68 shares in the last quarter. Impact Partnership Wealth LLC raised its position in shares of DaVita by 3.7% during the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company’s stock worth $290,000 after purchasing an additional 70 shares during the period. Contravisory Investment Management Inc. lifted its holdings in shares of DaVita by 1.2% during the 4th quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company’s stock valued at $910,000 after purchasing an additional 73 shares in the last quarter. Finally, Nilsine Partners LLC increased its stake in DaVita by 0.8% during the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company’s stock worth $1,669,000 after purchasing an additional 92 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on DVA shares. Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. StockNews.com lowered DaVita from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Finally, Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $166.33.

DaVita Price Performance

Shares of NYSE DVA opened at $150.29 on Monday. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The business has a 50-day moving average of $157.39 and a 200-day moving average of $157.55. The stock has a market capitalization of $12.02 billion, a price-to-earnings ratio of 13.99, a PEG ratio of 1.07 and a beta of 0.99. DaVita Inc. has a fifty-two week low of $125.64 and a fifty-two week high of $179.60.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, sell-side analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.